NY A 10521

in committee

Adds CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases to the newborn screening panel for New York state

New York · 2025-2026 Regular Session · lower

Quick answers

Did NY A 10521 pass?

Not yet. NY A 10521 is in committee as of 2026-04-07 and has not come to a final vote. Latest recorded action (2026-04-07): PRINT NUMBER 10521A

What is NY A 10521 about?

Adds CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases to the newborn screening panel for New York state; requires tests be made available within twelve months.

Who sponsors NY A 10521?

Andrew Hevesi is the primary sponsor of NY A 10521, joined by 7 cosponsors.

Description

Adds CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases to the newborn screening panel for New York state; requires tests be made available within twelve months.

Introduced: —
Latest action: 2026-04-07 — PRINT NUMBER 10521A
Bill type: bill
Last updated: —

Committees

Not provided by source.

Action timeline

2026-03-06
REFERRED TO HEALTH
referral-committee
2026-04-07
AMEND AND RECOMMIT TO HEALTH
amendment-passage,referral-committee
2026-04-07
PRINT NUMBER 10521A
amendment-passage

Versions

A10521Compare
A10521ACompare

Documents

Votes

Not provided by source.

Related bills

Companion bill: S 10260

Official source

https://legislation.nysenate.gov/api/3/bills/2025-2026/A10521?summary=&detail=

Attribution

Data from openstates_api_sync, retrieved 2026-07-24T11:45:38.857410Z

Inspect retained evidence for changes recorded after evidence tracking began:

Source and document changes Status and relationship changes

Use this data

Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=NY&identifier=A 10521. See the API docs or the MCP server for AI assistants.

Known limitations

Sponsor party and chamber affiliation are not yet captured by this API.
Committee referrals are not yet captured.

See the methodology page for data sources and limitations.